Handok Inc

Handok Inc operates with a debt-to-equity ratio of 1.01, indicating a balanced capital structure, but its liquidity position is rated as medium risk due to negative net cash after subtracting total debt. The company's price-to-book ratio of 0.34 suggests that the market values its equity at a significant discount to its book value, which may reflect concerns about asset quality or future earnings potential. Free cash flow is negative at -1.16 billion KRW, driven by capital expenditures of -4.7 billion KRW, indicating ongoing investment in operations.

Profitability metrics show a challenging operating environment for Handok Inc. The company reported a net loss of 2.25 billion KRW, with a return on equity of -0.67% and a return on assets of -0.28%, both significantly below the industry median for pharmaceutical firms. Gross profit of 43.49 billion KRW on revenue of 128.78 billion KRW yields a gross margin of 33.8%, which is in line with the industry average but insufficient to offset rising costs and declining net margins.

Geographically, Handok Inc is heavily concentrated in the South Korean market, with no disclosed international revenue streams. This concentration increases exposure to domestic regulatory shifts and currency fluctuations. The company's revenue is derived from a single business segment focused on prescription pharmaceuticals, with no diversification into medical research or biotechnology.

Looking ahead, Handok Inc is projected to see a modest improvement in revenue, with a 2.1% year-over-year increase in the current fiscal year and a 3.4% increase in the next fiscal year. However, these growth rates are below the industry median of 5.8% and may not be sufficient to restore profitability or improve liquidity. The company's operating cash flow of 401 million KRW is insufficient to cover capital expenditures, suggesting continued reliance on external financing or asset sales to fund operations.

Risk factors include a medium liquidity risk score and a negative net cash position, which could constrain the company's ability to respond to market opportunities or financial stress. The risk assessment also flags potential dilution pressure, though it is currently rated as low. The company's recent financial performance and capital structure suggest a need for careful monitoring of debt servicing and cash flow generation.

Recent filings and transcripts indicate that Handok Inc is focusing on cost optimization and product portfolio rationalization to improve margins. The company has also announced plans to expand its pipeline of generic drugs, which could provide a more stable revenue stream in the long term. However, the absence of significant R&D investment or new product launches in the near term may limit its ability to capture market share in a competitive industry.

Handok Inc (002390.KS) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals. This taxonomic update provides a clearer structural definition of the company’s operational focus, aligning its profile with the broader healthcare industry landscape. Alongside this classification, the company’s risk assessment framework has been initialized with specific metrics. Dilution risk is currently rated as low, suggesting a stable capital structure with minimal immediate threat of share value erosion from new issuances. Conversely, liquidity risk has been assessed at a medium level. This indicates that while the company maintains operational viability, there may be moderate constraints or volatility in its short-term cash flow management or market trading depth that warrants monitoring. These updates occur against a backdrop of limited external coverage, with only one analyst currently tracking the firm and no reported index memberships or top institutional holders. The establishment of these baseline risk and sector metrics offers a foundational reference point for future financial analysis of the stock.

Operating income surged 143.8% year-over-year to 7.09 billion KRW, signaling a strong recovery in core profitability.

Free cash flow turned positive to 2.48 billion KRW, marking a 104.7% improvement from the prior year's deficit.

Net income improved by 95.9% year-over-year, narrowing the loss significantly to just 2.15 billion KRW.

Revenue grew 5.5% year-over-year to 535.1 billion KRW, demonstrating resilient top-line performance despite market headwinds.

Long-term debt decreased from 373.4 billion KRW in FY-1 to 378.6 billion KRW in FY0, showing manageable leverage trends.

The company faces high credit risk, indicating significant concerns regarding its ability to meet financial obligations.

Debt-to-equity ratio stands at 1.01, placing it in the bottom quartile compared to the pharmaceutical cohort median of 0.18.

Cash conversion ratio of -0.18 places the firm in the bottom quartile versus the cohort median of 0.95.

Revenue KRW 543.76B, +5,0% YoY; Operating income −9,3% YoY.

• ▍Revenue KRW 543.76B, +5,0% YoY
• ▍Operating income −9,3% YoY
• ▍Net income +224,2% YoY
• ▍Free cash flow +29,1% YoY
• ▍Net margin 2.0%